%0 Journal Article %A Ata Abbas %A Morgan Gruner %A Jennifer Karohl %A Peter G. Rose %A Amy Joehlin-Price %A Hussein Al-Sudani %A Daniel Stover %A Haider Mahdi %T Circulating tumor fraction analyses with ultra-low pass whole genome sequencing predict response to chemoradiation and recurrence in stage IV small cell carcinoma of the cervix: a longitudinal case study %D 2020 %R 10.1101/2020.11.18.20233502 %J medRxiv %P 2020.11.18.20233502 %X Neuroendocrine carcinoma of the cervix is a rare and aggressive form of cervical cancer that presents with frequent metastasis at diagnosis and high recurrence rates. Primary treatment is multimodal, which often includes chemotherapy with or without radiation therapy. There is no data available to guide treatment for recurrence, and second-line therapies are extrapolated from small cell lung carcinoma data. Close monitoring of these patients for recurrence is paramount. Evaluation of circulating tumor DNA (ctDNA) in the peripheral blood is an attractive approach due to its noninvasive nature. Ultra-low pass whole genome sequencing (ULP-WGS) can assess tumor burden, response to therapy, and predict recurrence; however, data are lacking regarding the role of ULP-WGS in small cell carcinoma of the cervix. This study demonstrates a patient whose response to chemotherapy and cancer recurrence was accurately monitored by ctDNA using ULP-WGS testing and confirmed with radiologic imaging findings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot mentioned.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by IRB, Cleveland Clinic Foundation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available from the corresponding author on reasonable request. %U https://www.medrxiv.org/content/medrxiv/early/2020/11/20/2020.11.18.20233502.full.pdf